Radioactively labeled compounds (radiopharmaceuticals) are important molecular probes for the non-invasive detection of diseases with very high sensitivity. The development of radiopharmaceuticals in an interdisciplinary endeavor involving radiochemistry, radiopharmaceutical chemistry, biochemistry, molecular biology, pharmacy and pharmacology. At the Center for Radiopharmaceutical Sciences (CRS – a joint endeavor between the ETHZ and external page Paul Scherrer Institute), our interdisciplinary team is developing and testing novel radiopharmaceuticals for the detection of neurodegeneration, cardiovascular diseases and cancer. The most promising drug candidates are transferred into our unique clean room facilities that enable aseptic drug preparation and tested in humas trials with our clinical partners.